Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: dys, re your questions....Kidd

Jun 23, 2007 08:23AM

Jun 23, 2007 09:29AM
SGE

Jun 23, 2007 04:02PM

Jun 23, 2007 06:53PM

Jun 24, 2007 05:01AM

Jun 24, 2007 06:53AM

Jun 24, 2007 07:57AM

Jun 24, 2007 08:15AM

Jun 24, 2007 09:54AM

Jun 24, 2007 10:41AM

Jun 24, 2007 10:42AM

Jun 24, 2007 10:50AM

Jun 24, 2007 01:04PM

Jun 24, 2007 03:00PM

My being late to the table is in reference to this topic in which I figured was spoken about before I returned to posting on this thread. It was not to create an element of being a newbie (I could've posted a new idenity if I wanted to do that). I stepped away from reading and participating on this board until recently to do work on a major remodel on my home. I figured some people may have some information I did not have while I was looking through the 10-Q and PR's and bacially what initally caught my attention was the acceleration of warrant conversions from the end of Feb. to March 20th. Why the rush? In this enviroment of good news happening, the smothering of the SP is the only negative in this picture currently. I wasn't able to attend the SHM. There is an appearance through the warrant redemption program that warrants could have been taken off the board. One question I have is, was it used and to what extent (to mitigate the negative impact on day to day trading). Maybe one of you people already had that answer. In my digging around, I tend to inform as to what I'm looking at and why in order to avoid misconception and confusion. I'm not looking to gloom and doom anybody but as a shareholder I feel that if I'm finding any appearance of corporate deception, I will delve into it. As good news is happening at the front door, I'm trying to keep an eye out the back door.

Thanks Kidd and my best wishes to all who have helped in this discussion.

Share
New Message
Please login to post a reply